Skip to main content

Table 4 Variability in HER2 status among patients with recordings of both HER2 score and HER2 status

From: High inter-laboratory variability in the assessment of HER2-low breast cancer: a national registry study on 50,714 Danish patients

HER2 status

Negative

Positive

Score 0

HER2 low

In total

   

N

%

N

%

N

%

N

%

N

Capital Region

4017

26.3

9038

59.2

13,055

85.6

2202

14.4

15,257

 Dept. 1

1996

26.7

4394

58.8

6390

85.5

1087

14.5

7477

 Dept. 2

1943*

25.7

4532

60.0

6475

85.7

1083

14.3

7558

 Dept. 3

78

35.1

112

50.5

190

85.6

32

14.4

222

Zealand

2497

31.9

4261

54.4

6758

86.2

1079

13.8

7837

 Dept. 4

2497

31.9

4261

54.4

6758

86.2

1079

13.8

7837

Southern Denmark

2879

25.0

7134

61.9

10,013

86.9

1503

13.1

11,516

 Dept. 5

1128

34.3

1749

53.2

2877

87.6

408

12.4

3285

 Dept. 6

652*

26.1

1537

61.6

2189

87.8

305

12.2

2494

 Dept. 7

337

15.5

1559

71.6

1896

87.1

282

12.9

2178

 Dept. 8

762

21.4

2289

64.3

3051

85.7

508

14.3

3559

Central Denmark

1988

20.8

6155

64.5

8143

85.4

1397

14.6

9540

 Dept. 9

621

18.2

2389

70.0

3010

88.2

404

11.8

3414

 Dept. 10

101

22.9

265

60.1

366

83.0

75

17.0

441

 Dept. 11

215

11.0

1404

71.8

1619

82.8

336

17.2

1955

 Dept. 12

1051

28.2

2097

56.2

3148

84.4

582

15.6

3730

Northern Denmark

1603

37.9

2045

48.3

3648

86.2

584

13.8

4232

 Dept. 13

1126

38.4

1442

49.2

2568

87.6

363

12.4

2931

 Dept. 14

477

36.7

603

46.3

1080

83.0

221

17.0

1301

In total

12,984

26.8

28,633

59.2

41,617

86.0

6765

14.0

48,382

  1. *Discrepancy from Table 3 due to patients with a score of 0 and concurrent gene amplification, thus classified as HER2 positive